Impact of cytomegalovirus match on survival after cardiac and lung transplantation

American Surgeon

Volumn 70, Issue 8, 2004, Pages 710-714

  Bonatti, Hugo ^a   Tabarelli, Walther ^a   Ruttmann, Elfriede ^a   Kafka, Reinholf ^a   Larcher, Clara ^a   Höfer, Daniel ^a   Klaus, Alexander ^a   Laufer, Günther ^a   Geltner, Christian ^a   Margreiter, Raimund ^a   Müller, Ludwig ^a   Antretter, Herwig ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ACUTE DISEASE; ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; HEART TRANSPLANTATION; HUMAN; LONGITUDINAL STUDY; LUNG TRANSPLANTATION; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SURVIVAL;

ACUTE DISEASE; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 4544370295     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Hebart H, Einsele H. Diagnosis and treatment of cytomegalovirus infection. Curr Opin Hematol 1998;5:483-487 (Pubitemid 28521522)
2. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995;9: 863-877 (Pubitemid 26008606)
3. Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 1998;55: 59-72.
4. Halme M, Lautenschlager I, Halme L, et al. Ganciclovir prophylaxis after lung and heart-lung transplantation. Transpl Int 1998;11 (Suppl 1):S499-501. (Pubitemid 128683608)
5. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001;72:1647-1652
6. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001;11:73-81. (Pubitemid 32267778)
7. Gutierrez CA, Chaparro C, Krajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998;113:924-932 (Pubitemid 28216434)
8. Novick RJ, Menkis AH, McKenzie FN, et al. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status? J Heart Transplant 1990;9: 699-706.
9. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001;32:742-751 (Pubitemid 32221932)
10. Barrett-Muir WY, Aitken C, Templeton K, et al. Evaluation of the murex hybrid capture cytomegalovirus DNA assay versus plasma PCR and shell vial assay for diagnosis of human cytomegalovirus viremia in immunocompromised patients. J Clin Microbiol 1998;36:2554-2556 (Pubitemid 28380954)
11. Cantarovich M, Rene P, Latter D. Is the incidence of cytomegalovirus disease following heart transplantation decreased by prophylactic ganciclovir and CMV-hyperimmunglobulin? Transpl Int 1994;7(Suppl 1):S385-8.
12. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999;1(Suppl 1):8-12.
13. Snydman DR. Infection in solid organ transplantation. Transplant Infectious Disease 1999;1:21-28
14. Rubin RH, Ikonen T, Gummert JF, et al. The therapeutic prescriptions for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transplant Infectious Disease 1999;1:29-39.
15. Guetta E, Guetta V, Shibutani T, et al. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ Res 1997;81:8-16.
16. Kurz S, Steffens HP, Mayer A, et al. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 1997;71:2980-2987 (Pubitemid 27119941)
17. Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002;17:310-314 (Pubitemid 35453648)
18. Tuder RM, Weinberg A, Panajotopoulos N, et al. Cytomegalovirus infection amplifies class I major histocompatibility complex expression on cultured human endothelial cells. J Heart Lung Transplant 1994;13:129-138 (Pubitemid 24068949)
19. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J 1999;138: S469-72.
20. Koskinen PK, Kallio EA, Tikkanen JM, et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transplant Infectious Disease 1999;1:115-126
21. Harringer W, Haverich A. Heart and heart-lung transplantation: standards and improvements. World J Surg 2002;26: 218-225 (Pubitemid 36920435)
22. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097 (Pubitemid 34289682)
23. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transplant Infectious Disease 1999;1: 50-64.
24. Slifkin M, Tempesti P, Poutsiaka DD, et al. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001;33:E62-8.
25. Schnitzler MA, Woodward RS, Brennan DC, et al. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Am J Kidney Dis 1997;29:428-434
26. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001;3(Suppl 2)44-48 (Pubitemid 34073656)
27. Toyoda M, Galfayan K, Galera OA, et al. Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transpl Immunol 1997;5:104-111 (Pubitemid 27359387)
28. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir- resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002;21:1274-1282 (Pubitemid 35477741)
29. Rosenthal SL, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997;24:135-139 (Pubitemid 27081532)
30. Brumble LM, Milstone AP, Loyd JE, et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest 2002;121:407-414
31. Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int 1999;12:254-260 (Pubitemid 29423663)
32. Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001;3(Suppl 2)49-56. (Pubitemid 34073657)
33. Sharpies LD, Tamm M, McNeil K, et al. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - early risk factors. Transplantation 1996;61:560-566 (Pubitemid 126426022)